Performance
5 Days
0 0%
1 Month
0 0%
3 Months
-19.23%
6 Months
-40.01%
1 Year
-92.06%
2 Year
-99.67%
Key data
Stock price
$2.96
DAY RANGE
N/A - N/A
52 WEEK RANGE
$0.25 - $0.76
52 WEEK CHANGE
-$40.01
DIVIDEND
$0.00
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: James Sapirstein
Region: US
Website: https://www.azurrx.com/
Employees: 12
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:
Region: US
Website: https://www.azurrx.com/
Employees: 12
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry:
Sector:
azurrx biopharma aims to become a leader in developing non-systemic, recombinant protein therapies for the treatment of gastrointestinal diseases and related conditions. ms1819 recombinant lipase for exocrine pancreatic insufficiency is the lead development program with additional early stage research being conducted for the prevention of hospital-acquired infection. the company is headquartered in new york, ny, with scientific operations based in langlade, france.
Recent news